Implantica AG Makes Capital Markets Day Webcast Available

VADUZ, Liechtenstein, Sept. 11, 2026 /CourierPR/ -- Implantica AG, a medical technology company focused on advanced implantable technologies, has made its Capital Markets Day webcast available for on-demand viewing. The event, held on September 9, 2026, in Stockholm, provided insights into the company’s U.S. rollout strategy following the recent FDA approval of its RefluxStop® device.

The webcast, which can be accessed via the provided link, featured a series of presentations and discussions. It began with a welcome address from Tomas Puusepp, a Board Member of Implantica AG. Dr. Peter Forsell, the CEO and Founder of the company, then provided an update on the company’s vision and strategy. Amit Kukreja, the COO and President of U.S. Operations, discussed the commercial strategy and market opportunity in the U.S. Juanita Eberhart, the VP of Marketing and Advocacy, elaborated on the U.S. marketing strategy.

The event also included a Q&A session with Dr. Forsell, Kukreja, and Eberhart. Following this, Dr. John C. Lipham from the University of Southern California shared his clinical experience and outlook on the RefluxStop® procedure. Two patient testimonials were included, one from Mrs. Sallyann Warner, a patient who had undergone the procedure, and another from a surgeon who is himself a patient of RefluxStop®.

The webcast concluded with a panel discussion and Q&A session involving Dr. Lipham, Dr. J. Daniel Sánchez from Cirugía Laparoscópica Madrid, Dr. Peter Forsell, Amit Kukreja, and Juanita Eberhart. This comprehensive coverage allowed viewers to gain a detailed understanding of Implantica’s strategy and the potential impact of the RefluxStop® device on the treatment of gastroesophageal reflux disease (GERD).

RefluxStop® is designed to address the root cause of acid reflux by maintaining the lower esophageal sphincter in its natural anatomical position without encircling or applying pressure on the food passageway. The device has shown promising results in clinical studies, with long-term 5-year outcomes supporting its effectiveness. Implantica AG, listed on the Nasdaq First North Premier Growth Market in Stockholm, continues to advance its product pipeline, including an eHealth platform for communication and remote monitoring of implants, and a wireless energizing platform for powering implantable devices.